Which laboratory change indicates a therapeutic response to an antihyperlipidemic medication?

Which laboratory change indicates a therapeutic response to an antihyperlipidemic medication?

• A. Decreased high density lipoprotein (HDL) cholesterol
• B. Increased triglyceride level
• C. Decreased low density lipoprotein (LDL) cholesterol
• D. Increased bilirubin level

Answer: (C)

Lowering LDL cholesterol is the main measure of response to antihyperlipidemic therapy. These medications aim to reduce the amount of atherogenic LDL particles in the blood, and a decrease in LDL-C on a lipid panel reflects that beneficial effect and is closely linked to reduced cardiovascular risk. HDL is the protective lipoprotein, and therapies do not rely on decreasing it to indicate success; a lower HDL would not signal a positive response. Triglycerides may change with some treatments, but they are not the primary/most reliable marker of efficacy for most antihyperlipidemics. An increase in bilirubin would point to possible liver injury, not a therapeutic benefit. So, the lab change that best signals a therapeutic response is a decrease in LDL cholesterol.

Lowering LDL cholesterol is the main measure of response to antihyperlipidemic therapy. These medications aim to reduce the amount of atherogenic LDL particles in the blood, and a decrease in LDL-C on a lipid panel reflects that beneficial effect and is closely linked to reduced cardiovascular risk.

HDL is the protective lipoprotein, and therapies do not rely on decreasing it to indicate success; a lower HDL would not signal a positive response. Triglycerides may change with some treatments, but they are not the primary/most reliable marker of efficacy for most antihyperlipidemics. An increase in bilirubin would point to possible liver injury, not a therapeutic benefit.

So, the lab change that best signals a therapeutic response is a decrease in LDL cholesterol.